Abstract

Info

Title:: Therapeutic efficacy of simultaneous integrated boost versus conventional intensity-modulated radiotherapy in esophageal cancer

Author(s):: GUO Hao; ZHOU Shuni; DING Hua; JIANG Xueping; RAN Ruizhi; Department of Oncology, the Central Hospital of Enshi Tujia and Miao Autonomous Prefecture (Enshi Clinical College of Wuhan University), Enshi 445000, China

Keywords:: Keywords: simultaneous integrated boost intensity-modulated radiotherapy conventional intensity-modulated radiotherapy esophageal cancer therapeutic efficacy serum tumor factor prognosis adverse reaction

Abstract:: Abstract: Objective To investigate the therapeutic efficacy of simultaneous integrated boost intensity-modulated radiotherapy (SIB-IMRT) and conventional IMRT in the treatment of esophageal carcinoma. Methods A retrospective analysis was conducted on 149 cases of esophageal cancer. According to different treatment methods, they were divided into simultaneous group (n=77) and conventional group (n=72). The patients in simultaneous group were treated with SIB-IMRT, while those in conventional group received conventional IMRT. The clinical efficacy, levels of squamous cell carcinoma antigen (SCC), carbohydrate antigen 125 (CA125) and carcinoembryonic antigen (CEA), physical fitness score (Karnofsky score), quality of life score (SF-36 score), and adverse reactions were compared between two groups after treatment. Results The total effective rate of simultaneous group was higher than that of conventional group (93.51% vs 81.94%, P<0.05). Compared with conventional group, simultaneous group had lower levels of SCC, CA125 and CEA (P<0.05), higher Karnofsky score and SF-36 score (P<0.05), and fewer cases of adverse reactions. Conclusion Both SIB-IMRT and conventional IMRT have certain clinical effects in the treatment of esophageal cancer. However, SIB-IMRT is advantageous over IMRT in therapeutic efficacy for SIB-IMRT can effectively control the high expression of serum tumor factors, improve the prognosis, and reduce the incidence of adverse reactions.